208 related articles for article (PubMed ID: 9559780)
41. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion.
Hanson LH; Stevens DA
Antimicrob Agents Chemother; 1992 Feb; 36(2):486-8. PubMed ID: 1605618
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis.
Sidhu R; Lash DB; Heidari A; Natarajan P; Johnson RH
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686150
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections.
Linden P; Williams P; Chan KM
Clin Transplant; 2000 Aug; 14(4 Pt 1):329-39. PubMed ID: 10945204
[TBL] [Abstract][Full Text] [Related]
44. Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against Candida embedded in biofilm.
Raad II; Hachem RY; Hanna HA; Fang X; Jiang Y; Dvorak T; Sherertz RJ; Kontoyiannis DP
Int J Antimicrob Agents; 2008 Dec; 32(6):515-8. PubMed ID: 18783924
[TBL] [Abstract][Full Text] [Related]
45. Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients.
Saliba F; Delvart V; Ichaï P; Kassis N; Botterel F; Mihaila L; Azoulay D; Adam R; Castaing D; Bretagne S; Samuel D
Med Mycol; 2013 Feb; 51(2):155-63. PubMed ID: 22800082
[TBL] [Abstract][Full Text] [Related]
46. Amphotericin B-copper(II) complex as a potential agent with higher antifungal activity against Candida albicans.
Chudzik B; Tracz IB; Czernel G; Fiołka MJ; Borsuk G; Gagoś M
Eur J Pharm Sci; 2013 Aug; 49(5):850-7. PubMed ID: 23791641
[TBL] [Abstract][Full Text] [Related]
47. Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity.
Walker S; Tailor SA; Lee M; Louie L; Louie M; Simor AE
Antimicrob Agents Chemother; 1998 Apr; 42(4):762-6. PubMed ID: 9559779
[TBL] [Abstract][Full Text] [Related]
48. Comparative in vitro antifungal susceptibility activity of amphotericin B versus amphotericin B methyl ester against Candida albicans ocular isolates.
Thanathanee O; Miller D; Ringel DM; Schaffner CP; Alfonso EC; O'Brien TP
J Ocul Pharmacol Ther; 2012 Dec; 28(6):589-92. PubMed ID: 22788845
[TBL] [Abstract][Full Text] [Related]
49. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis.
Cicogna CE; White MH; Bernard EM; Ishimura T; Sun M; Tong WP; Armstrong D
Antimicrob Agents Chemother; 1997 Feb; 41(2):259-61. PubMed ID: 9021176
[TBL] [Abstract][Full Text] [Related]
51. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents.
Quindós G; Carrillo-Muñoz AJ; Arévalo MP; Salgado J; Alonso-Vargas R; Rodrigo JM; Ruesga MT; Valverde A; Pemán J; Cantón E; Martín-Mazuelos E; Pontón J
Chemotherapy; 2000; 46(6):395-401. PubMed ID: 11053905
[TBL] [Abstract][Full Text] [Related]
52. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model.
Goldblum D; Rohrer K; Frueh BE; Theurillat R; Thormann W; Zimmerli S
Antimicrob Agents Chemother; 2002 Dec; 46(12):3719-23. PubMed ID: 12435667
[TBL] [Abstract][Full Text] [Related]
53. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis.
Perfect JR; Wright KA
J Antimicrob Chemother; 1994 Jan; 33(1):73-81. PubMed ID: 8157577
[TBL] [Abstract][Full Text] [Related]
54. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.
Sharkey PK; Graybill JR; Johnson ES; Hausrath SG; Pollard RB; Kolokathis A; Mildvan D; Fan-Havard P; Eng RH; Patterson TF; Pottage JC; Simberkoff MS; Wolf J; Meyer RD; Gupta R; Lee LW; Gordon DS
Clin Infect Dis; 1996 Feb; 22(2):315-21. PubMed ID: 8838189
[TBL] [Abstract][Full Text] [Related]
55. Comparative in vitro studies on liposomal formulations of amphotericin B and its derivative, N-methyl-N-D-fructosyl amphotericin B methyl ester (MFAME).
Cybulska B; Kupczyk K; Szlinder-Richert J; Borowski E
Acta Biochim Pol; 2002; 49(1):67-75. PubMed ID: 12136958
[TBL] [Abstract][Full Text] [Related]
56. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells.
Legrand P; Chéron M; Leroy L; Bolard J
J Drug Target; 1997; 4(5):311-9. PubMed ID: 9169988
[TBL] [Abstract][Full Text] [Related]
57. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
Zhang Z; Diener RM; Lipman JM
Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
[TBL] [Abstract][Full Text] [Related]
58. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.
Hussain A; Samad A; Singh SK; Ahsan MN; Haque MW; Faruk A; Ahmed FJ
Drug Deliv; 2016; 23(2):642-47. PubMed ID: 25013957
[TBL] [Abstract][Full Text] [Related]
59. Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients.
Bassetti M; Aversa F; Ballerini F; Benedetti F; Busca A; Cascavilla N; Concia E; Tendas A; Di Raimondo F; Mazza P; Nosari AM; Rossi G
Clin Drug Investig; 2011 Nov; 31(11):745-58. PubMed ID: 21888451
[TBL] [Abstract][Full Text] [Related]
60. Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients.
Oravcová E; Mistrík M; Sakalová A; Drgona L; Kollár T; Helpianska L; Ilavská I; Sorkovská D; Spánik S; Kukucková E
Chemotherapy; 1995; 41(6):473-6. PubMed ID: 8529439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
